Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc.
Your view on BJDX
Overview
What the company does, where it operates, and who runs it.
About Bluejay Diagnostics, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Indranil Dey
- Headquarters
- 360 Massachusetts Avenue, Acton, MA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Indranil Dey
- Headquarters
- 360 Massachusetts Avenue, Acton, MA, US
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States.
It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure.
It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bluejay Diagnostics, Inc., and the rating behind it. BJDX last traded at $0.90; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bluejay Diagnostics, Inc.. Starting points for Bluejay Diagnostics, Inc.: EPS -$3.50, beta 0.91 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bluejay Diagnostics, Inc.. Bluejay Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bluejay Diagnostics, Inc.. Trailing twelve-month EPS for Bluejay Diagnostics, Inc. stands at -$3.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bluejay Diagnostics, Inc.. Bluejay Diagnostics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bluejay Diagnostics, Inc. valued side by side against its closest peers. Bluejay Diagnostics, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bluejay Diagnostics, Inc., and how their positions are changing. At a $928,449 market value, institutional positions materially move Bluejay Diagnostics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bluejay Diagnostics, Inc. executives and directors. Shares of Bluejay Diagnostics, Inc. have traded between $1.26 and $10.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bluejay Diagnostics, Inc.. Bluejay Diagnostics, Inc. is a $928,449 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bluejay Diagnostics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bluejay Diagnostics, Inc.. Coverage tracks Bluejay Diagnostics, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.